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Abstract
Background: The origin and development of breast cancer remain complex and obscure. Recently, microRNA
(miRNA) has been identified as an important regulator of the initiation and progression of breast cancer, and some
studies have shown the essential role of miR-124-3p as a tumor suppressor in breast tumorigenesis. However, the
detailed role of miR-124-3p in breast cancer remains poorly understood.
Methods: Quantitative RT-PCR and western blotting assays were used to measure miR-124-3p and CBL expression
levels in breast cancer tissues, respectively. Luciferase reporter assay was employed to validate the direct targeting
of CBL by miR-124-3p. Cell proliferation and invasion assays were performed to analyze the biological functions of
miR-124-3p and CBL in breast cancer cells.
Results: In the present study, we found that miR-124-3p was consistently downregulated in breast cancer tissues.
Moreover, we showed that miR-124-3p significantly suppressed the proliferation and invasion of breast cancer cells.
In addition, we investigated the molecular mechanism through which miR-124-3p contributes to breast cancer
tumorigenesis and identified CBL (Cbl proto-oncogene, E3 ubiquitin protein ligase) as a direct target gene of
miR-124-3p. Moreover, we found that ectopic expression of CBL can attenuate the inhibitory effect of miR-124-3p on
cell proliferation and invasion in breast cancer cells.
Conclusions: This study identified a new regulatory axis in which miR-124-3p and CBL regulate the proliferation and
invasion of breast cancer cells.
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Background
Breast cancer is the leading cause of death in women
and is the most common type of cancer. Although ad-
vances in the diagnosis and treatment of breast cancer
have greatly reduced its incidence and mortality, there
are still 500,000 breast cancer deaths per year worldwide
[1, 2]. An improved understanding of the molecular
mechanisms of this disease is needed for developing new
treatments.
MicroRNAs (miRNAs) are non-coding RNAs that are
small size and single stranded and regulate most of
biological processes, including cell proliferation, dif-
ferentiation, migration and apoptosis. MiRNAs cause
post-transcriptional silencing of target mRNAs by
binding to their 3’-untranslated regions (3’-UTRs)
through complementary base pairing [3]. During the
initial and subsequent developmental stages of human can-
cers, miRNAs can function either as oncogenes or tumor
suppressors [4–6]. For example, miR-124-3p, a brain-
enriched miRNA involved in the regulation of gastrulation
and neural development [7, 8], has recently been reported
to function as a tumor suppressor through targeting some
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important genes, such as RAC1, the androgen receptor,
SPHK1, ROCK2 and EZH2 [9]. Although these studies
have shown the potential role of miR-124-3p as a
tumor-suppressive miRNA during tumorigenesis [10, 11],
the detailed function of miR-124-3p in the initiation and
progression of breast cancer remains poorly understood.
In this study, we measured the expression levels of miR-
124-3p in 10 pairs of breast cancer and matched adjacent
noncancerous tissue samples and found that miR-124-3p
levels were downregulated in breast cancer tissues. Using
bioinformatics algorithms, we predicted CBL (Cbl proto-
oncogene, E3 ubiquitin protein ligase) as a target gene of
miR-124-3p. Furthermore, we showed that miR-124-3p
could suppress CBL expression and negatively regulate
the proliferation and invasion of breast cancer cells.
Methods
Cells and human tissues
The human breast cancer cell lines MCF-7 and MDA-
MB-231 were obtained from the Shanghai Institute of
Biochemistry and Cell Biology, Chinese Academy of
Sciences (Shanghai, China). MCF-7 and MDA-MB-231
cells were cultured in DMEM and L15, respectively;
both media were supplemented with 10 % fetal bovine
serum (FBS, GIBCO, CA, USA) and were placed in in-
cubator at 37 °C in a humidified 5 % CO2 atmosphere.
Breast cancer and normal adjacent tissues are provided
by the The First Affiliated Yijishan Hospital with Wannan
Medical College (Wuhu, China) from patients during sur-
gery. All protocols concerning the use of patient samples
in this study were approved by the Medical Ethics Com-
mittee of the The First Affiliated Yijishan Hospital with
Wannan Medical College (Wuhu, China) All samples col-
lection is done following guidelines of Institutional Review
Board–approved protocol after a written agreement ap-
proval by the patients. Liquid nitrogen is used to freeze
samples soon after their collection from surgery and later
on stored at -80 °C. The clinical features of the patients
are listed in Additional file 1: Table S1.
RNA isolation and quantitative RT-PCR
TRIzol Reagent (Invitrogen, Carlsbad, CA) is used to extract
total RNA according to manufacturer’s guidelines. Stem-
loop quantitative RT-PCR (qRT-PCR) assays using TaqMan
miRNA probes (Applied Biosystems) were performed to
quantify the levels of mature miRNAs on Applied Biosys-
tems 7300 Sequence Detection System (Applied Biosys-
tems). The reactions were incubated in a 96-well optical
plate at 95 °C for 10 min, followed by 40 cycles at 95 °C for
15 s and 60 °C for 1 min. The relative levels of the miRNAs
in cells and tissues were normalized to U6. By using the
2-△△CT equation, miRNA amount was calculated relative
to the internal control U6, where △△CT = (CT miRNA -
CT U6)tumor - (CT miRNA - CT U6)control.
To quantify CBL mRNA, 1 μg of total RNA was
reverse-transcribed to cDNA using oligo dT and AMV
reverse transcriptase (TaKaRa, Dalian, China) and
incubated at 16 °C for 30 min, followed by 42 °C for
30 min and 85 °C for 5 min. Real-time PCR was
performed using SYBR Green Dye (Invitrogen) and
CBL and GAPDH primers. Primers sequences were: CBL
(sense): 5’-TGACATCTTTACCCGACTC-3’; CBL (anti-
sense): 5’-CATACCCAATAGCCCAC-3’; GAPDH (sense):
5’-GATATTGTTGCCATCAATGAC-3’; and GAPDH
(antisense): 5’-TTGATTTTGGAGGGATCTCG-3’. The
relative amount of CBL mRNA was normalized to
GAPDH.
miRNA overexpression or knockdown
In order to achieve miR-124-3p overexpression, cells
were transfected with miR-124-3p mimic (a mimicking
precursor of miR-124-3p that is double-stranded syn-
thetic RNA oligonucleotide) as previously described [12].
Knockdown of miR-124-3p was achieved by transfecting
cells with miR-124-3p antisense (a chemically modified
antisense oligonucleotide designed to target mature miR-
124-3p) as previously described [12]. Synthetic miR-124-
3p mimic (pre-miR-124-3p), antisense (anti-miR-124-3p)
and scrambled negative control RNAs (pre-miR-control
and anti-miR-control) were bought from GenePharma
(Shanghai, China). MCF-7 and MDA-MB-231 were trans-
fected with Lipofectamine 2000 (Invitrogen) in 6-well
plates when cells were approximately 70 % confluent. Old
medium was replaced with new DMEM or L15 supple-
mented with 2 % FBS after 6 h.
A mammalian expression plasmid encoding human CBL
open reading frame (ORF) was obtained from GeneCopoeia
(pReceiver-M02-CBL, Germantown, MD, USA). For nega-
tive control, an empty plasmid was used. The siRNA (se-
quence: 5’-CCUAGUCUCCUCUAUCGCUTT-3’) targeting
human CBL was designed and synthesized by GenePharma.
A scrambled siRNA (GenePharma) was also used as a
negative control. MCF-7 cells were transfected with overex-
pression plasmid or siRNA by using Lipofectamine 2000
(Invitrogen) following manufacturer’s instructions. After 24
or 48 h, total RNA or protein were extracted.
Western blotting
The protein levels were analyzed by western blot using
the appropriate antibodies. Anti-GAPDH antibody was
applied to the same blots to normalize protein levels.
Detail of antibodies and corresponding sources from
where these were purchased are as follows: anti-c-CBL
(610442; BD Biosciences, USA) and anti-GAPDH (sc-
365062; Santa Cruz Biotechnology, Santa Cruz, CA,
USA). ImageJ software was used for protein bands
analysis.
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Luciferase reporter assay
Luciferase reporter assay was done as previously de-
scribed to predict the direct binding of miR-124-3p to
the target gene CBL [13]. PGL3 plasmid encoding a
luciferase report gene was purchased from Ambion.
The recombinant plasmid PGL3-CBL-3’-UTR was
constructed by inserting the sequence of CBL 3’-UTR
into the PGL3 plasmid. DNA sequencing was per-
formed to confirm successful insertion. The mutant
3’-UTR sequence of CBL was directly synthesized and
inserted into the equivalent reporter plasmid by Gene-
Pharma (all three binding sites were mutated). For
luciferase reporter assay, HEK293T cells were transfected
using Lipofectamine 2000 (Invitrogen) by seeding HEK293T
cells in 24-well plates and then each well of the plate was
transfected with 0.1 μg of a β-galactosidase (β-gal) expres-
sion plasmid (Ambion), 0.1 μg of firefly luciferase reporter
plasmid and 100 pmol of pre-miR-124-3p. Scrambled RNA
was used as a negative control and β-gal plasmid as a
transfection control. The cells were assayed using a
luciferase assay kit 24 h after transfection (Promega,
Madison, WI, USA).
Cell proliferation assay
For each well in 96-well plates, 5 × 103 MCF-7 cells were
seeded and transfected 24 h later. After transfection, 10
μl WST-8 solution from the Cell Counting Kit-8 (CCK8,
Beyotime, China) was added into each well. Absorbance
of each well was measured after 2 h incubation by read-
ing plates at 450 nm at time 12, 24, 36 and 48 h. The
relative cell number was calculated as the ratio of ab-
sorbance at 24, 36 and 48 h to12 h.
Cell invasion assay
Transwell invasion assay was performed using Transwell
Boyden Chambers (6.5-mm, Costar, USA) with inserts that
have membrane with pore size of 8-μm and a slim Matrigel
layer. About 12 h after transfection, cells were harvested,
suspended in DMEM culture medium that did not contain
FBS and then loaded to upper chamber (2 × 104 cells/well).
Then 500 μl DMEM medium that contained 10 % FBS was
added to the lower compartment at the same time and the
plates were placed for incubation for 7 h in 5 % CO2-hu-
midified atmosphere. After 7 h incubation, lower surface of
the filter membrane that contained migrant cells was col-
lected and fixed with 4 % paraformaldehyde at room
temperature for 25 min. Membrane washing is done by dis-
tilled water for three times and the membrane is then
stained with 0.1 % crystal violet in methanol at room
temperature for 15 min. Non-migrant cells that remained
on the upper surface of the filter membrane were collected
by gentle scrapping using a cotton swab. Migrant cells in
lower surface were analyzed by photomicroscope (BX51
Olympus, Japan), and the cells were counted blindly (five
fields per chamber).
Statistical analysis
All data of western blot images presented here is selected
from minimum three separate experiments. Luciferase re-
porter assay, qRT-PCR assay, cell proliferation and invasion
assay were conducted three times and with many repeti-
tions. The results presented here is the means ± SE of mini-
mum three separate experiments. The differences were
analyzed by Student’s t-test and considered statistically sig-
nificant at P < 0.05.
Results
Expression patterns of miR-124-3p in breast cancer
tissues
To investigate the roles of miR-124-3p in human breast
cancer, we first determined the expression pattern of
miR-124-3p in breast cancer tissues. By measuring the
miR-124-3p levels in 10 pairs of breast cancer tissues
and normal adjacent tissues, we found that miR-124-3p
levels were consistently downregulated in breast cancer
tissues (Fig. 1a).
miR-124-3p functions as a tumor suppressor in breast
cancer cells
Next, we investigated the biological effects of miR-124-3p
on breast cancer cells. First, we overexpressed miR-124-3p
in a human breast cancer cell line (MCF-7) and used
CCK8 assay to examine the effect of miR-124-3p on cell
proliferation. We found that the number of proliferating
cells was significantly reduced after transfection of MCF7
cells with miR-124-3p mimic but increased after transfec-
tion with miR-124-3p antisense (Fig. 1b and c). Addition-
ally, we checked the effects of miR-124-3p on cell invasion
using the Transwell assay. The invasion rate was signifi-
cantly decreased after transfection of MCF7 cells with
miR-124-3p mimic but increased after transfection with
miR-124-3p antisense (Fig. 1d and e). These data indicate
that miR-124-3p might inhibit the proliferation and inva-
sion of breast cancer cells and act as a tumor-suppressive
miRNA during breast tumorigenesis.
Prediction of CBL as a target of miR-124
To explore the mechanism through which miR-124-3p
influences breast cancer cell proliferation and invasion, a
list of predicted targets of miR-124-3p was compiled
using the bioinformatics algorithms TargetScan [14],
miRanda [15] and PicTar [16]. Among the candidates,
CBL, an oncogene that is frequently observed to be up-
regulated in breast cancer [17], was selected and further
investigated. As shown in Fig. 2a, there were three pre-
dicted targeting sites of miR-124-3p within the 3’-UTR
of CBL. The minimum free energy values of the three
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hybridizations were -17.0, -20.1 and -24.5 kcal/mol, and
these hybridizations had perfect base-pairing between
the seed sequences (the 2nd to 8th bases of the mature
miRNA) and the cognate targets.
We next examined if miR-124-3p had expression pat-
terns that are opposite to CBL in breast cancer. By meas-
uring CBL protein levels in the same 10 pairs of breast
cancer tissues and normal adjacent tissues, we found that
CBL was consistently upregulated in the breast cancer tis-
sues (Fig. 2b and c). Thus, CBL was selected as a target of
miR-124-3p, based on both computational predictions
and their inverse correlation in breast cancer tissues.
Validation of the direct targeting of CBL by miR-124-3p
To further validate the correlation between miR-124-3p
and CBL, we overexpressed or knocked down miR-124-3p
in MCF-7 and MDA-MB-231 breast cancer cell lines and
assessed the protein levels of CBL. As anticipated, the cel-
lular levels of miR-124-3p were dramatically increased in
MCF-7 and MDA-MB-231 cells after transfection with
miR-124-3p mimic and dropped significantly after treat-
ment with miR-124-3p antisense (Fig. 3a). Consequently,
CBL protein levels were decreased in MCF-7 and MBA-
MD-231 cells by the introduction of miR-124-3p, while
the antisense of miR-124-3p significantly increased the
CBL protein levels in these two breast cancer cell lines
(Fig. 3b and c).
Subsequently, a luciferase reporter assay was performed
to confirm that miR-124-3p directly targets the predicted
binding sites in the CBL 3’-UTR and negatively regulates
CBL expression. The CBL 3’-UTR sequence was inserted
downstream of the firefly luciferase gene in a reporter plas-
mid. The recombination plasmid was transfected along
with miR-124-3p mimic into HEK293T cells. As expected,
Fig. 1 miR-124-3p functions as a tumor suppressor in breast cancer. a qRT-PCR analysis of the expression levels of miR-124-3p in 10 pairs of breast cancer
tissue (BC) and noncancerous tissue (NC) samples. b and c CCK8 analysis of the proliferation rate in MCF-7 cells treated with control mimic or miR-124-3p
mimic (b), or with control antisense or miR-124-3p antisense (c). d and e) Transwell analysis of invaded MCF-7 cells treated with control mimic, miR-124-3p
mimic, control antisense or miR-124-3p antisense. d representative image; e quantitative analysis. *P< 0.05; **P< 0.01
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the luciferase activity was markedly reduced in cells co-
transfected with luciferase reporter plasmid and miR-124-
3p mimic (Fig. 3d). We then introduced point mutations
into the predicted miR-124-3p binding sites in the CBL 3’-
UTR to eliminate the potential interaction between miR-
124-3p and CBL. As a result, overexpression of miR-124-3p
had no effect on the mutated luciferase reporter activity
(Fig. 3d), suggesting that the binding sites strongly contrib-
ute to the interaction between miR-124-3p and CBL. In
summary, miR-124-3p directly binds to the CBL 3’-UTR
and suppresses CBL translation.
miR-124-3p suppresses tumor proliferation and invasion
through targeting CBL
We next analyzed the biological consequences of the
repression of CBL by miR-124-3p. Because CBL is well
known to promote tumor proliferation and invasion
[18, 19], we examined if miR-124-3p would modulate
CBL to influence the proliferation and invasion of
breast cancer cells. We designed a siRNA sequence
targeting CBL ORF to knockdown CBL and con-
structed a plasmid expressing the full-length CBL ORF
to overexpress CBL without the miR-124-responsive
3’-UTR. Efficient overexpression or knockdown of
CBL was observed in MCF-7 cells after transfection
with CBL overexpression plasmid and CBL siRNA, re-
spectively (Additional file 2: Figure S1). Transfection
of CBL siRNA markedly reduced the number of prolif-
erating MCF-7 cells, whereas transfection of the CBL
overexpression plasmid promoted cell proliferation
(Fig. 4a and b). Thus, the inhibition of cell prolifera-
tion by CBL knockdown is equivalent to miR-124-3p
overexpression. Additionally, cells transfected with
miR-124-3p mimic and the CBL overexpression plasmid
showed higher proliferation rates compared to cells trans-
fected with miR-124-3p mimic alone (Fig. 4c), suggesting
that miR-124-3p-resistant CBL could sufficiently rescue the
suppression of CBL by miR-124-3p and attenuate the anti-
proliferative effect of miR-124-3p on breast cancer cells.
We also evaluated the effects of miR-124-3p-mediated
suppression of CBL expression on the invasion of breast
cancer cells using the Transwell invasion assay. Silencing
of CBL expression using specific siRNA significantly de-
creased the number of MCF-7 cells that invaded through
the Transwell membrane, while overexpression of CBL
using specific plasmid markedly promoted cell invasion
Fig. 2 Prediction of CBL as a target of miR-124-3p. a Diagram illustrating the hypothetical duplexes formed by interactions between the binding
sites in the CBL 3’-UTR (top) and miR-124-3p (bottom). The predicted free energy value of each hybrid is indicated. The seed recognition sites are
denoted; all nucleotides in these regions are highly conserved across species, including human, mouse and rat. b and c Western blot analysis of
the expression levels of CBL protein in 10 pairs of BC and NC samples. b representative image; c quantitative analysis
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(Fig. 4d and f). Thus, the inhibition of cell invasion by
CBL knockdown is equivalent to miR-124-3p overex-
pression. Additionally, when MCF-7 cells were simultan-
eously transfected with the miR-124-3p mimic and the
CBL overexpression plasmid, CBL dramatically attenu-
ated the inhibitory effect of miR-124-3p on cell invasion
(Fig. 4e and g). In summary, miR-124-3p might suppress
the proliferation and invasion ability of breast cancer
cells by targeting CBL.
Discussion
Breast cancer cause highest number of deaths globally
and is the most common type of cancer among women
[20, 21]. The development of new treatments is halted
mainly because of drug resistance and less knowledge
about tumor cell signaling pathways. Over the past
decade, a class of small, non-coding, single-stranded
RNAs known as miRNAs has emerged as major regula-
tors of the initiation and progression of human cancers,
Fig. 3 CBL is a direct target of miR-124-3p. a qRT-PCR analysis of the expression levels of miR-124-3p in MCF-7 and MDA-MB-231 cells treated
with control mimic, miR-124-3p mimic, control antisense or miR-124-3p antisense. b and c Western blot analysis of the expression levels of CBL
protein in MCF-7 and MDA-MB-231 cells treated with control mimic, miR-124-3p mimic, control antisense or miR-124-3p antisense. b representative
image; c quantitative analysis. d Firefly luciferase reporters containing wild-type (WT) or mutant (MUT) miR-124-3p binding sites in the CBL 3’-UTR were
co-transfected into HEK293T cells together with control mimic or miR-124-3p mimic. The cells were assayed using a luciferase assay kit 24 h
post-transfection. *P < 0.05; **P < 0.01; ***P < 0.001
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Fig. 4 Effects of miR-124-3p and CBL on the proliferation and invasion of MCF-7 cells. a–c CCK8 analysis of the proliferation rate of MCF-7 cells
treated with control siRNA or CBL siRNA (a), with control plasmid or CBL plasmid (b), or with one of the combinations: control mimic plus control
plasmid, miR-124-3p mimic plus control plasmid, control mimic plus CBL plasmid, or miR-124-3p mimic plus CBL plasmid (c). d–g Transwell
analysis of invaded MCF-7 cells treated with control siRNA or CBL siRNA (d), with control plasmid or CBL plasmid (d), or with one of the
combinations: control mimic plus control plasmid, miR-124-3p mimic plus control plasmid, control mimic plus CBL plasmid, or miR-124-3p
mimic plus CBL plasmid (e). d and e representative images; f and g quantitative analysis. *P < 0.05; **P < 0.01; ***P < 0.001
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including breast cancer [22, 23]. Importantly, dysregu-
lated and dysfunctional miRNAs play a causal role in
cancer etiology because miRNAs can affect the transla-
tion and stability of targeted oncogenes and tumor sup-
pressors, which eventually influences cellular physiology
[4–6]. In the present study, we detected significant re-
duction of miR-124-3p in breast cancer tissues. As one
of the most enriched miRNAs in the brain of mammals
[24], miR-124-3p is involved in both brain development
and neuronal function [25, 26]. Recently, miR-124-3p
has been identified as a tumor suppressor in some can-
cers, including hepatocellular carcinoma [27], cervical
cancer [28] and gastric cancer [29]. However, the func-
tion of miR-124-3p in breast cancer is largely unknown.
In the present study, we found that miR-124-3p can sup-
press the proliferation and invasion of breast cancer
cells, suggesting that miR-124-3p may play a critical role
in the negative regulation of growth and metastasis of
breast cancer. Accumulating evidence suggests that pro-
liferation and invasion of cells are very important in
carcinogenesis and its progression [30]. The results indi-
cate that miR-124-3p may serve as an ideal therapeutic
target for breast cancer. Additional work is needed to
characterize the feasibility of targeting miR-124-3p in
cancer therapy and develop simplified and cost-
effective methods.
The CBL families are highly conserved ubiquitin ligases.
Thus far, three mammalian homologs have been defined —
CBL (also known as c-CBL), CBL-b and CBL-c — which
vary from one another on the basis of difference in length
of C termini and their property to work as adaptors [31].
Among the three homologs of the family, CBL is mainly
known as a ubiquitin E3 ligase that is responsible for signal
transduction in different cell types against various types of
stimuli [32, 33]. It is thought that the predominant function
of CBL is causing ubiquitination of active RTKs thereby
resulting in negative regulation of their signaling and direct-
ing them towards lysosomes to degrade [34]. From this
point of view, CBL may act mainly as a tumor suppressor
in the pathogenesis of human cancers. For example, some
studies revealed a role of CBL in restricting tumor cell pro-
liferation and invasion [35, 36]. Conversely, CBL is regarded
as a proto-oncogene with numerous mutations and import-
ant roles in some cancers, including myeloid neoplasms
[37], colorectal cancer [38] and glioma [19]. Thus, if CBL
acts as a tumor suppressor or an oncogene is dependent on
the cell and tumor types. Under different circumstances,
CBL may exert opposite functions. In breast cancer, the ex-
pression profile of CBL has not been systematically investi-
gated and the precise function of this gene remains unclear.
Overall, the findings of this study demonstrated that CBL is
overexpressed in human breast cancer tissues and that the
aberrant expression of CBL is responsible for the malignant
behaviors of breast cancer cells. Consistently, it was
reported that CBL blocks the tumor suppressor activity
of TGF-β and enhances breast tumor formation [17].
Furthermore, the molecular mechanism accounting for
the aberrant upregulation of CBL in breast cancer was
investigated. Mechanistic studies revealed that miR-
124-3p directly binds the CBL 3’-UTR and inhibit CBL
expression, and that CBL overexpression sufficiently
attenuates the inhibitory effects of miR-124-3p on
breast cancer cell proliferation and invasion. Therefore,
the modulation of CBL by miR-124-3p may explain
why the downregulation of miR-124-3p can promote
the development of breast cancer.
Conclusion
Overall, this study demonstrates that miR-124-3p possesses
tumor suppressor activity by negatively regulating CBL ex-
pression in breast cancer. The findings may provide insight
into the molecular mechanism of breast cancer and open
new avenues for cancer therapy.
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